Clinical trial
Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in…
NCT00243230 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00243230 |
|---|---|
| Title | Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Participants (VICTOR-E1) (MK-7690-020/P03672) |
| Official title | Vicriviroc (SCH 417690) in Combination Treatment With Optimized ART Regimen in Experienced Subjects (VICTOR-E1) |
| Acronym | VICTOR-E1 |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Vicriviroc 30 mg, Vicriviroc 20 mg, Placebo, Background ART Regimen |
| Enrollment | 116 |
| Start date | Sep 19, 2005 |
| Primary completion | Oct 19, 2007 |
| Completion | Mar 17, 2011 |
| First posted | Oct 21, 2005 |
| Last update posted | Jun 8, 2021 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: